biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF
Aptose Biosciences
Aptose Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker APTOF. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, C
San Diego, USA HQ
2014 Founded
32 Employees
Public company Type
APTOF · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 32
- Programs
- 8
- Drugs
- 1
- Patents
- 7
APTO-253
Phase 1 · small molecule · Acute Myelogenous Leukemia in Relapse
APTO-253 for Acute Myelogenous Leukemia in Relapse is a Phase 1 program (small_molecule) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).
Internal code 253-HEM1-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aptose Biosciences
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Acute Myelogenous Leukemia in Relapse
- Status
- terminated
- Trials
- 1